Recently, p73, a new member of the p53 family, has been cloned and mapped to chromosome 1p36, a region that is frequently deleted in a variety of human cancers. p73 can activate p53-responsive promoters and induce apoptosis when overexpressed in certain p53-de®cient tumor cells. In contrast to p53, analysis of the p73 gene in several human solid tumors did not reveal loss of p73 expression or mutations in the p73 gene. However, transcriptional silencing of the p73 gene by hypermethylation of a CpG island was observed in several leukemias and lymphomas. These lymphoid neoplasms also show increased expression of vascular endothelial growth factor (VEGF), an endothelial cell-speci®c mitogen and a key mediator of angiogenesis. To evaluate a possible relationship between p73 status and VEGF expression, we have studied the eect of ectopically expressed p73 on the regulation of the VEGF gene. Our results demonstrate that p73 can down-regulate endogenous VEGF gene expression on mRNA and protein level. This eect is mediated by transcriptional repression of the VEGF promoter and involves the promoter region 785 to 750 bp, containing a cluster of Sp 1 binding sites. Our results suggest a regulatory role for p73 in tumor angiogenesis. Oncogene (2000) 19, 3470 ± 3476.
Introduction
p53 is the most frequently mutated tumor suppressor gene identi®ed to date (Hollstein et al., 1991; Levine et al., 1991) . Loss or inactivation of p53 function is thought to contribute to the development of about 50% of all human cancers (Hollstein et al., 1991; Levine et al., 1991) . Recently, a gene encoding a novel p53-like protein was identi®ed (Kaghad et al., 1997) . This gene, p73, maps to chromosome 1p36, a region that is frequently deleted in a variety of human cancers (Kaghad et al., 1997) .
Because p73 encodes a protein that is structurally homologous to the p53 protein, it has been postulated to be a new candidate tumor suppressor gene. In agreement with the high structural homology between p73 and p53, it was shown that p73 was capable of activating the cyclin-dependent kinase inhibitor gene p21 (Kaghad et al., 1997; Jost et al., 1997) and when overexpressed in cells it inhibits growth in a p53-like manner by inducing apoptosis (Jost et al., 1997) . The apoptotic activity of p73 requires the presence of functional, kinase-competent c-Abl, which serves as an upstream protein kinase for p73 able to phosphorylate p73 in response to DNA-damaging agents (Yuan et al., 1999; Agami et al., 1999) .
In contrast to p53, mutational analysis of the p73 gene in several human solid tumors did not reveal loss of p73 expression or mutations in the p73 gene (Mai et al., 1998; Sunahara et al., 1998; Kroiss et al., 1998) . On the other hand, transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma was reported, suggesting that silencing of the p73 gene by hypermethylation may contribute to development of lymphoid neoplasms (Corn et al., 1999; Kawano et al., 1999) .
A prerequisite for solid tumor growth is the sprouting of new capillaries from pre-existing blood vessels, a process called tumor angiogenesis (Hanahan and Folkman, 1996) . The vascular endothelial growth factor (VEGF) has been described as a key mediator of this process . The VEGF mRNA is expressed predominantly in tumor cells and stromal cells, whereas the mRNAs for the VEGF receptors VEGF-R1 and VEGF-R2 are expressed and upregulated in tumor endothelial cells (Suzuki et al., 1996) . This expression pattern is consistent with the hypothesis that VEGF acts primarily as a paracrine regulator of tumor angiogenesis.
A great variety of cytokines and growth factors have been shown to upregulate VEGF mRNA expression (Frank et al., 1995; Gille et al., 1997; Cohen et al., 1996; Finkenzeller et al., 1992) . Activated oncogenes or inactivated tumor suppressor genes also contribute to the upregulation of VEGF expression in tumor cells (Kolch et al., 1995) . Recently, it was reported that VEGF expression is not only upregulated in solid tumors but also in various human hematopoietic neoplasms (Hussong et al., 2000; Bellamy et al., 1999) . In acute myeloid leukemia (AML), increased VEGF levels correlate with shorter survival, as well as shorter disease-free survival suggesting that VEGF is a predictor of outcome in patients with acute myeloid leukemia (Aguayo et al., 1999) . Moreover, VEGF was shown to suppress apoptotic cell death induced by ionizing radiation in hematopoietic cells, suggesting that VEGF may give leukemia cells resistance against radiotherapy (Katoh et al., 1995 (Katoh et al., , 1998 .
Because in leukemias and lymphomas, p73 expression is impaired due to transcriptional silencing of the p73 gene and because these neoplasms are also characterized by increased VEGF expression, we intended to investigate whether p73 might have a suppressive eect on VEGF expression. For this purpose, we examined the eect of ectopically expressed p73 on the regulation of the VEGF gene in p53 de®cient Saos-2 cells with no detectable p73 expression as well as in A293 cells. We could demonstrate that p73 inhibits endogenous VEGF expression on mRNA and protein levels. Moreover, by using various VEGF promoter constructs, we could demonstrate that p73 down-regulated VEGF promoter activity. This eect was mediated at least in part by the promoter region 785/750 containing a cluster of Sp 1 binding sites. Our results suggest a role for p73 in the inhibition of tumor progression by down-regulation of VEGF expression.
Results

Expression of p73 in Saos-2 and A293 cells
In order to obtain a high level of p73 expression in transient transfection assays, the hemagglutinin-tagged cDNA of p73a (Jost et al., 1997) was subcloned into the pVP22/myc-His expression vector. This expression vector was designed for expression of proteins fused to the viral protein VP22, which allows translocation of the fusion protein out of the transfected cells into neighboring non-transfected cells and accumulation in recipient cell nuclei. Western blot analysis revealed high expression of the p73/pVP22 fusion protein in the p53 de®cient Saos-2 osteosarcoma cell line, which does not express detectable levels of endogenous p73 (Kaghad et al., 1997) (Figure 1a ). High levels of expression of the p73/pVP22 fusion protein were also obtained in human fetal kidney A293 cells 68 h after transfection (Figure 1b) .
Effect of p73 on VEGF expression and VEGF promoter activity
In order to investigate the eect of p73 on the expression of the VEGF gene, mRNA levels of VEGF were determined in A293 cells, 68 h after transfection. As shown in Figure 2a , mRNA levels of VEGF were considerably decreased in cells transfected with p73/pVP22 in comparison to cells transfected with empty vector. VEGF protein levels in the conditioned media of control or p73/pVP22-transfected cells were investigated by ELISA ( Figure  2b ). Saos-2 and A293 cells produced 5.1 and 8.8 ng respectively per 10 6 cells within 68 h. Expression of p73 in Saos-2 and A293 cells reduced VEGF protein levels by 37 and 51%, respectively. As an internal control for p73 function, expression of the p21 protein, which is known to be induced in response to p73 expression (Jost et al., 1997) , was analysed by Western blotting 68 h after transfection in Saos-2 cells ( Figure 2c ). As expected, expression of p21 was strongly elevated in p73/pVP22-transfected cells in comparison to mock-transfected cells. Similar results were obtained with A293 cells (data not shown). These results demonstrate that p73 expression in these cell types can positively, as in the case of p21, and negatively, as in the case of VEGF, interfere with gene expression.
Based on the results that p73 inhibits the expression of VEGF mRNA and protein, we investigated the eect of p73 expression on the transcriptional regulation of the VEGF promoter. For this purpose, we used the Saos-2 osteosarcoma cell line, because this cell line harbors a homozygous deletion at the p53 gene locus (Diller et al., 1990) and does not express detectable amounts of endogenous p73 protein (Kaghad et al., 1997) . Moreover, Figure 1 Expression of p73. Saos-2 cells (a) and A293 cells (b) were transiently transfected with the control vector (7) or the p73 expression plasmid p73/pVP 22 (+), using the calcium phosphate precipitation method. Sixty-eight hours after transfection, cellular proteins (100 mg/lane) were separated by 7.5%-SDS ± PAGE and blotted onto nitrocellulose membranes. HA-tagged p73/VP22 fusion proteins were detected using a monoclonal anti-HA antibody. The p73/VP22 fusion protein shows a molecular weight of approximately 120 kDa on SDS ± PAGE this cell line is well characterized with respect to the eect of ectopically expressed p73 on transcriptional activation of p53 target genes and cell growth (Jost et al., 1997) . Saos-2 cells were transiently cotransfected with a VEGF promoter-luciferase-reporter plasmid pLuc 2068 (Finkenzeller et al., 1997) , bearing the VEGF promoter region 72018 to +50, and the p73 expression plasmid pCDNA/p73. As shown in Figure 3 , co-transfection of pLuc 2068 with p73 resulted in a strong repression of the VEGF promoter activity. In contrast, the promoter activity of PG13-luc, a construct containing multimerized p53 binding sites of the ribosomal gene cluster (Kern et al., 1992; Mekle et al., 1998) , was considerably elevated in response to p73 co-transfection, as previously reported (Jost et al., 1997) . This eect is dependent on the p53 binding sites, since introduction of speci®c point mutations into the p53 binding sites of the PG13-luc mut construct (Kern et al., 1992) , completely abolished p73 inducibility. (7) or with the p73 expression plasmid p73/pVP22 (+). (a) Northern blot analysis of VEGF mRNA expression in p73 transfected A293 cells. Sixty-eight hours after transfection, RNA was isolated and 10 mg were analysed by Northern blotting using a VEGF 165 cDNA probe. (b) VEGF protein expression in p73 transfected Saos-2 and A293 cells. Sixty-eight hours after transfection, the conditioned media were collected and assayed for VEGF protein by an ELISA assay. VEGF protein levels of control-transfected cells was set as 100%. Data with error bars (s.d.) are from four independent experiments performed in triplicate. (c) Western blot analysis of p21 expression in p73 transfected Saos-2 cells. Sixty-eight hours after transfection, cellular proteins (60 mg/lane) were separated by 12.5%-SDS ± PAGE, blotted on nitrocellulose and probed with a polyclonal anti-p21 antibody Identification of cis-acting elements, necessary for p73-mediated down-regulation of VEGF promoter activity
To de®ne the regions within the VEGF promoter that confer p73 repression of promoter activity, we used a series of VEGF promoter deletion mutants (Finkenzeller et al., 1997) . These 5'-deletion mutants have variable 5'-ends (from 72018 bp in pLuc 2068 to 752 bp in pLuc 102) and an identical 3'-end at bp +50 (relative to the transcriptional start site). The VEGF promoter reporter plasmids were co-transfected with either a p73 expression plasmid or an empty control vector into Saos-2 cells. As shown in Figure 4a , consecutive removal of the regions located between 72018 and 752 caused a decline in the repressing eect of p73 on promoter activity, ranging from 67%-inhibition in the pLuc 2068 construct to 37%-inhibition in the pLuc 135 construct. However, removal of the promoter region 785 to 752 (pLuc 102) decreased basal promoter activity and completely abolished p73 responsiveness, suggesting that the VEGF promoter region 785 to 752 may play a role in p73-mediated transcriptional repression.
To further determine whether this promoter region may play a role in down-regulation of promoter activity by p73, the promoter region 785 to 750 was cloned into the heterologous thymidine kinase promoter-luciferase test plasmid pTATA, thus generating pTATA (785/750) (Finkenzeller et al., 1997) . As shown in Figure 4b , cells transfected with pTA-TA(785/750) expressed 3.5-fold greater luciferase activity as compared to cells transfected with the control plasmid pTATA. Co-transfection of pTA-TA(785/750) with a p73 expression plasmid repressed promoter activity of this construct by approximately 78%, whereas the control plasmid pTATA was not aected by p73. This result indicates that insertion of the 785/750 VEGF promoter region into the heterologous thymidine kinase promoter construct, confers responsiveness to p73.
The 785/750 VEGF promoter region contains three putative Sp 1 and two putative Egr-1 binding sites. To investigate the contribution of these sites to the transcriptional regulation by p73, we used reporter constructs in which the putative Sp 1 sites (pLuc 135/ Sp 1 mut) or the Egr-1 sites (pLuc 135/Egr-1 mut) have been mutated. These mutated VEGF promoter reporter gene constructs were transiently co-transfected with the p73 expression plasmid and compared with the wildtype control (pLuc 135). As shown in Figure 4c , the plasmid with the point mutations in the Sp 1 binding sites showed a reduced basal promoter activity in relation to the wild-type reporter pLuc 135. Interestingly, the Sp 1 mutant is no longer responsive to cotransfected p73. In contrast, mutations in the putative Egr-1 binding sites did not in¯uence p73 responsiveness of the VEGF promoter. This result suggests the involvement of Sp 1 binding sites in the transcriptional regulation of the VEGF promoter by p73.
In summary, this study suggests the VEGF gene as a target for p73 function. Ectopical expression of p73 down-regulates expression of VEGF on mRNA and protein level. This eect seems to be mediated by transcriptional repression of the VEGF promoter, involving Sp 1 binding to the 785 to 750 promoter region.
Discussion
In this study, we have investigated the role of the p53 homolog p73 in the regulation of VEGF expression. Ectopically expressed p73 down-regulated endogenous VEGF gene expression on mRNA and protein level. This eect could be observed in A293 cells as well as in Saos-2 cells, the latter harboring a homozygous deletion at the p53 gene locus (Diller et al., 1990) and not expressing detectable amounts of the p73 protein (Kaghad et al., 1997) . This repressing eect of p73 was selective for VEGF expression, since we could show that expression of the cell cycle inhibitor p21 gene, a known target gene for p73 (Jost et al., 1997) , was considerably elevated in p73 transfected cells. Moreover, we have seen in transient transfection assays that co-transfection of a p73 expression plasmid together with a VEGF promoter/reporter plasmid inhibited the VEGF promoter activity in Saos-2 cells. This ®nding is in agreement with the repressing eect of p73 in the genomic context of endogenous VEGF expression, where VEGF is down-regulated on mRNA as well as on protein level. This result suggests that transcriptional repression of the VEGF gene, represents the mechanism by which p73 down-regulates VEGF production.
To de®ne the regions within the VEGF promoter that confer p73 responsiveness, we have used various VEGF promoter deletion-and point-mutants (Finken- , 1997) . Using the 5'-deletion constructs of the human VEGF promoter, a gradual decline in the repressing eect of co-transfected p73 on the VEGF promoter could be observed, ranging from 67%-inhibition for the longest construct (pLuc 2068) to 37%-inhibition for the shortest construct (pLuc 135), containing the promoter region 785 to +50. However, further deletion of 35 bp in the pLuc 102 reporter plasmid, decreased basal promoter activity and completely abolished p73 responsiveness, suggesting that this promoter region may play a role in p73 mediated transcriptional repression. Indeed, when this 35 bp VEGF promoter fragment was fused to a minimal thymidine kinase promoter, it was able to confer p73 responsiveness to the heterologous thymidine kinase promoter/reporter construct. Moreover, mutation within the Sp 1 binding sites in the promoter fragment, abolished p73-responsiveness, suggesting that the eect of p73 on the VEGF promoter is mediated by the proximal Sp 1 binding sites in the 785 to 750 promoter region. Interestingly, these potential Sp 1 binding sites have been implicated in the regulation of VEGF expression by the platelet-derived growth factor (PDGF) (Finkenzeller et al., 1997) as well as by the tumor suppressor genes von Hippel Lindau (VHL) (Mukhopadhyay et al., 1997) and p53 (Mukhopadhyay et al., 1995) . The results presented here indicate that these Sp 1 binding sites also play a role in p73 mediated repression of the VEGF promoter. However, the fact that we have detected a gradual decline in the p73 responsiveness of the VEGF promoter upon consecutive shortening of the promoter from the 5'-end suggests that there may exist additional cis-acting elements upstream of the 785 to 750 promoter region, which may contribute to the repressing eect of p73 on VEGF promoter activity. It was reported that p73 not only transactivates p53 responsive promoters but also binds to canonical p53 consensus sequences in electrophoretic mobility shift assays (Marin et al., 1998) . Remarkably, the VEGF promoter does not possess a p53 binding site. Therefore direct binding of p73 to the VEGF promoter is unlikely. Further analysis of the VEGF promoter is required to localize all cis-acting elements responsible for the repressing eect of p73.
The data suggest, that the observed inhibitory eect of p73 on VEGF expression is implicated in tumor angiogenesis. Spontaneously arising tumor cells are not usually angiogenic. The gain of an angiogenic phenotype itself depends on a net balance of positive and negative angiogenic factors released by the tumor. Interestingly, the p73 homolog p53 has been implicated in the regulation of this angiogenic balance by controlling the expression of the anti-angiogenic factor thrombospondin as well as by controlling expression of the angiogenic factor VEGF. In this context, it was shown that in cultured ®broblasts from Li-Fraumeni patients, loss of wild-type p53 coincides with reduced expression of the angiogenesis inhibitor thrombospondin-1 (TSP-1) (Dameron et al., 1994) . Moreover, transient transfection assays revealed that p53 can stimulate the endogenous TSP-1 gene expression by activating the TSP-1 promoter. This indicates that wt p53 inhibits angiogenesis at least in part, through stimulation of TSP-1 expression. The inhibitory eect of p53 on tumor angiogenesis is also mediated by a repressing eect of p53 on expression of the angiogenic factor VEGF (Mukhopadhyay et al., 1995) . In this context, p73 behaves similar to p53, in its inhibitory eect on VEGF expression. It remains to be seen, whether p73 is also able to augment thrombospondin-1 expression, similar to p53.
VEGF is not only a mitogen for vascular endothelial cells but also functions as a survival factor for these cells (Gerber et al., 1998a) . This is consistent with data showing that VEGF induces expression of antiapoptotic proteins, such as Bcl-2 in human endothelial cells (Gerber et al., 1998b) . Therefore, interference with the VEGF/VEGF-receptor systems leads to apoptotic cell death of endothelial cells resulting in regression of the tumor vasculature accompanied by tumor regression. This implies that tumor suppressor genes such as p53 and its homolog p73 do not only play a role in tumor cell proliferation but are also able to modulate endothelial cell survival functions, by inhibiting VEGF expression in tumor cells.
In summary, our results show for the ®rst time that p73 can function as a transcriptional repressor of the VEGF gene promoter and suggest a role for p73 in angiogenesis by repressing VEGF expression. Ongoing work will clarify the molecular mechanism(s) involved in p73 mediated repression of VEGF expression.
Materials and methods
Plasmid constructions
The construction of the various VEGF luciferase plasmids, pLuc 2068, pLuc 465, pLuc 135, pLuc 102, pLuc 135/SP 1 mut, pLuc 135/Egr-1 mut, pTATA and pTATA(785/750) was described in detail previously (Finkenzeller et al., 1997) . The p73 expression plasmid pcDNA3-p73a containing the p73a cDNA with an amino-terminal hemagglutinin (HA) epitope (Jost et al., 1997) was a gift from Dr D Caput. The luciferase reporter plasmid pGL2-PG13-luc contains 13 copies of the RGC p53 binding site (Kern et al., 1992) , linked to a luciferase reporter gene (Mekle et al., 1998) . To generate the expression plasmid p73/pVP22, pcDNA3-p73a was digested with BamHI and StuI and the resulting 2.9 kb fragment containing the amino-terminal HA-epitope-tagged p73a cDNA was subcloned into the BamHI-and EcoRV sites of pVP22/myc-His (Invitrogen) in frame with the VP22 open reading frame. From this construct, p73 is expressed as a VP22 fusion protein which allows translocation of the VP22-p73 fusion protein through the medium to adjacent cells.
Cell culture and transfection
Saos-2 and A293 cells were grown in Dulbecco's modi®ed eagle medium (DMEM), supplemented with 10% fetal calf serum, 100 U/ml penicillin and 100 U/ml streptomycin, in 378C, 10% CO 2 . For transient transfections, 2610 6 cells were plated on 100 mm petridishes. Twenty-four hours later, cells were transfected with 10 mg of the p73 expression plasmid p73/pVP22 or 10 mg of the vector control plasmid pVP22/ myc-His, using the calcium phosphate-DNA coprecipitation method (Chen and Okayama, 1988) . Sixty-eight hours after transfection, cells were used for VEGF-ELISA, Western-or Northern-blot analysis. For luciferase assays, cells were transfected with 2 mg of the indicated reporter plasmids, 1 mg of pCMV b-gal (Stratagene) and 2 mg of the p73 expression plasmid pcDNA3-p73a or the empty expression vector pcDNA3 (Invitrogen). Forty-eight hours after transfection, luciferase activities were assayed as described (Finkenzeller et al., 1997) .
VEGF-ELISA
VEGF protein levels in conditioned media of Saos-2 and A 293 cells were determined using a commercial VEGF-ELISA according to the protocol of the manufacturer (R&D Systems).
Western blot analysis
Cells were lysed on ice by the addition of lysis buer (50 mM Tris-HCl, pH 8.0, 120 mM NaCl, 0.5% NP-40, 11.5 mg/ml aprotinin, 5 mg/ml leupeptin, 50 mg/ml phenylmethane-sulphonyl¯uoride (PMSF), 100 mM NaF, 0.2 mM sodium orthovanadate). The protein concentration was determined using the BCA protein assay kit (Pierce). Proteins were separated by SDS-polyacrylamide gel electrophoresis, transferred to Hybond ECL nitrocellulose membranes (Amersham) and probed with antibodies against the hemagglutinin epitope (anti-HA antibody; 12CA5; Boehringer-Mannheim) or p21
waf1 (WAF1/Ab-5; Calbiochem). Bound proteins were detected using an ECL Western blotting detection system (Amersham).
Northern blot analysis
Northern blot analysis was performed as described previously (Finkenzeller et al., 1995) . The probe used for hybridization was a 0.6 kb EcoRI-BamHI VEGF 165 cDNA fragment (Weindel et al., 1992) . After washing, ®lters were autoradiographed using a Kodak X-OMAT X-ray ®lm with an intensifying screen.
